Yescarta

Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
Flag link:
Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Flag link:
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
Flag link:
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Fierce Pharma
Gilead Sciences
Kite Pharma
Bristol Myers Squibb
cell therapy
legal
CAR-T
Yescarta
Flag link:
Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA
Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA
Fierce Pharma
Gilead Sciences
Yescarta
Europe
diffuse large B-cell lymphoma
high-grade B-cell lymphoma
Flag link:
Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead
Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead
Biopharma Reporter
Kite Pharma
Gilead Sciences
FDA
CAR-T
drug manufacturing
Yescarta
Flag link:
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
Fierce Pharma
Gilead Sciences
oncology
cancer
Yescarta
Trodelvy
Flag link:
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst
Fierce Pharma
Gilead Sciences
Yescarta
CAR-T
Flag link:
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
Fierce Pharma
Gilead Sciences
Yescarta
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:
New fault lines emerge in CAR-T therapy
New fault lines emerge in CAR-T therapy
EP Vantage
CAR-T
Novartis
Kymriah
Bristol Myers Squibb
Beyanzi
Gilead Sciences
Yescarta
clinical trials
Flag link:
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Endpoints
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
CAR-T
Flag link:
#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle
#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle
Endpoints
Novartis
ASCO 2021
CAR-T
Kymriah
follicular lymphoma
Gilead Sciences
Yescarta
Flag link:
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Biopharma Reporter
Kite Pharma
Yescarta
CAR-T
Flag link:
ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy
ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy
Fierce Pharma
Gilead Sciences
Kite Pharma
Yescarta
diffuse large B-cell lymphoma
clinical trials
Flag link:
Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas
Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas
MedCity News
Gilead Sciences
Yescarta
follicular lymphoma
marginal zone lymphoma
ASCO 2020
Kite Pharma
Flag link:
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
Amsterdam
drug manufacturing
Flag link:
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
Fierce Pharma
Gilead Sciences
Yescarta
ASH2019
CAR-T
refractory large B-cell lymphoma
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:

Pages